Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
808 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT00863655 | Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole(BOLERO-2) | completed | Phase 3 | 724 | Novartis PharmaceuticalsINDUSTRY |
| 24 |
| May 2, 2017 |
| clinicaltrials |
| NCT00045032 | Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer(HERA) | completed | Phase 3 | 5,099 | Hoffmann-La RocheINDUSTRY | 33 | Apr 27, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT02036164 | Adjuvant Chemotherapy for Locally Advanced Cervical Cancer(ACT-LACC) | unknown | Phase 3 | 500 | Siriwan Tangjitgamol, MDOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| NCT01007942 | Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer(BOLERO-3) | completed | Phase 3 | 569 | Novartis PharmaceuticalsINDUSTRY | 21 | Apr 5, 2017 | clinicaltrials |
| NCT01217697 | Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer | approved for marketing | — | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 24 | Mar 24, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 | clinicaltrials |
| NCT00140582 | Primary Rituximab and Maintenance | completed | Phase 3 | 1,217 | Lymphoma Study AssociationOTHER | 12 | Mar 13, 2017 | clinicaltrials |
| NCT02144012 | A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer | terminated | Phase 3 | 49 | Hoffmann-La RocheINDUSTRY | 4 | Mar 7, 2017 | clinicaltrials |
| NCT03052621 | Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer | completed | — | 40 | Queen Sirikit Centre for Breast CancerOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT00806819 | Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC | completed | Phase 3 | 718 | Boehringer IngelheimINDUSTRY | 32 | Feb 2, 2017 | clinicaltrials |
| NCT01435200 | Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy | completed | Phase 3 | 64 | Chulalongkorn UniversityOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT01562821 | Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy | completed | Phase 2 | 235 | Novo Nordisk A/SINDUSTRY | 3 | Jan 13, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT00903175 | Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma(RECORD-3) | completed | Phase 2 | 471 | Novartis PharmaceuticalsINDUSTRY | 19 | Nov 8, 2016 | clinicaltrials |
| NCT00806923 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 1,044 | Hoffmann-La RocheINDUSTRY | 20 | Nov 2, 2016 | clinicaltrials |
| NCT01437566 | Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy | completed | Phase 2 | 318 | Genentech, Inc.INDUSTRY | 23 | Nov 2, 2016 | clinicaltrials |
| NCT01662869 | A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer | completed | Phase 3 | 564 | Hoffmann-La RocheINDUSTRY | 24 | Nov 2, 2016 | clinicaltrials |
| NCT02576964 | A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer | completed | Phase 2 | 16 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT00812175 | Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib(GIDEON) | completed | — | 3,371 | BayerINDUSTRY | 39 | Oct 17, 2016 | clinicaltrials |
| NCT00858871 | First Line Hepato Cellular Carcinoma (HCC)(BRISK FL) | completed | Phase 3 | 1,714 | Bristol-Myers SquibbINDUSTRY | 26 | Oct 17, 2016 | clinicaltrials |
| NCT01419197 | A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy(TH3RESA) | completed | Phase 3 | 602 | Hoffmann-La RocheINDUSTRY | 22 | Oct 12, 2016 | clinicaltrials |
| NCT00069095 | A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 2,035 | Hoffmann-La RocheINDUSTRY | 33 | Oct 6, 2016 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT00312377 | ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer(ZODIAC) | completed | Phase 3 | 1,690 | Genzyme, a Sanofi CompanyINDUSTRY | 25 | Sep 30, 2016 | clinicaltrials |
| NCT00404924 | ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures | completed | Phase 3 | 1,140 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Sep 30, 2016 | clinicaltrials |
| NCT01035229 | Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.(EVOLVE-1) | completed | Phase 3 | 546 | Novartis PharmaceuticalsINDUSTRY | 18 | Sep 22, 2016 | clinicaltrials |
| NCT02558569 | The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block | completed | Phase 4 | 128 | Mahidol UniversityOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT01389986 | Effects of Gum Chewing on Recovery of Bowel Function Following Abdominal Surgery for Endometrial and Ovarian Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Chiang Mai UniversityOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02398916 | Music Listening to Reduce Pain and Anxiety During LEEP | completed | N/A | 150 | Chiang Mai UniversityOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT00071188 | ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 9 | Aug 25, 2016 | clinicaltrials |
| NCT01590719 | A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer | completed | Phase 2 | 123 | Hoffmann-La RocheINDUSTRY | 6 | Aug 9, 2016 | clinicaltrials |
| NCT01460472 | Immunotherapy With Racotumomab in Advanced Lung Cancer | unknown | Phase 3 | 1,082 | Recombio SLINDUSTRY | 7 | Jul 29, 2016 | clinicaltrials |
| NCT02057367 | Scalp Nerve Block and Opioid Consumption in Brain Surgery | completed | Phase 4 | 100 | Chiang Mai UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT00656136 | BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) | completed | Phase 3 | 585 | Boehringer IngelheimINDUSTRY | 15 | Jul 26, 2016 | clinicaltrials |
| NCT00958841 | Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin | terminated | Phase 2 | 118 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 26, 2016 | clinicaltrials |
| NCT01325428 | Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer | completed | Phase 2 | 26 | Boehringer IngelheimINDUSTRY | 7 | Jul 19, 2016 | clinicaltrials |
| NCT01546233 | Multidisciplinary Education in Lung Cancer Patients Who Receiving Chemotherapy Treatment | completed | — | 60 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT02768428 | Effectiveness of Knowledge by Video and Handbook of Liver Cancer Patients With First Trans-arterial Chemoembolization | unknown | N/A | 80 | Chulabhorn HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT00257608 | A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) | completed | Phase 3 | 1,145 | Genentech, Inc.INDUSTRY | 17 | Apr 18, 2016 | clinicaltrials |
| NCT00338247 | EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | approved for marketing | — | — | NovartisINDUSTRY | 45 | Apr 6, 2016 | clinicaltrials |
| NCT02317757 | Predisposing Factors Associated With Chemotherapy Toxicity in Elderly Cancer Patients | unknown | — | 150 | Mahidol UniversityOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01876693 | A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy | terminated | N/A | 95 | Mahidol UniversityOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01297491 | Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer(BASALT-1) | completed | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 11, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT02608073 | A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | Hoffmann-La RocheINDUSTRY | 5 | Mar 2, 2016 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials